Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: Exemplified by activity of an mGlu2/3 receptor agonist

Psychopharmacology

Volumn 214, Issue 2, 2011, Pages 505-514

  Dedeurwaerdere, Stefanie ^a   Wintmolders, Cindy ^a   Straetemans, Roel ^a   Pemberton, Darrel ^a   Langlois, Xavier ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

2 deoxyglucose; Antipsychotics; Mice; NMDA antagonist; Schizophrenia

Indexed keywords

CARBON 14; CLOZAPINE; DEOXYGLUCOSE; HALOPERIDOL; KETAMINE; MEMANTINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RESPONSE; DRUG SCREENING; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MOUSE; NEUROPHYSIOLOGY; NONHUMAN; OLFACTORY BULB; ORBITAL CORTEX; PRIORITY JOURNAL; PYRIFORM CORTEX; SCREENING TEST; STRATUM LACUNOSUM MOLECULARE; THALAMUS; THALAMUS NUCLEUS; VALIDITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL TRANSPORT; BRAIN; CARBON RADIOISOTOPES; CYCLIC S-OXIDES; DEOXYGLUCOSE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; HIGH-THROUGHPUT SCREENING ASSAYS; KETAMINE; MALE; MEMANTINE; MICE; MICE, INBRED C57BL; RECEPTORS, METABOTROPIC GLUTAMATE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 79952280209     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2052-z     Document Type: Article

References (42)

1. GM Alley JA Bailey D Chen B Ray LK Puli H Tanila PK Banerjee DK Lahiri 2010 Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice J Neurosci Res 88 143 154 19642202 10.1002/jnr.22172 1:CAS:528:DC%2BD1MXhtl2qtb%2FM
2. A Breier AK Malhotra DA Pinals NI Weisenfeld D Pickar 1997 Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers Am J Psychiatry 154 805 811 9167508 1:STN:280: DyaK2szhtVensw%3D%3D (Pubitemid 27230103)
3. ET Brown Y Umino DA Loi E Solessio R Barlow 2005 Anesthesia can cause sustained hyperglycemia in C57/BL6J mice Vis Neurosci 22 22 615 618 16332272 1:STN:280:DC%2BD2Mnlt1eqtw%3D%3D (Pubitemid 43237756)
4. V Colangelo GR Di F Passarelli M Musicco FE Pontieri F Orzi 1997 Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat Brain Res 768 273 278 9369325 10.1016/S0006-8993(97)00650-1 1:CAS:528:DyaK2sXlslelt7w%3D (Pubitemid 27433501)
5. PJ Conn A Christopoulos CW Lindsley 2009 Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat Rev Drug Discov 8 41 54 19116626 10.1038/nrd2760 1:CAS:528:DC%2BD1cXhsFCkurfF
6. N Dawson L Ferrington HJ Olverman PA Kelly 2008 Novel analysis for improved validity in semi-quantitative 2-deoxyglucose autoradiographic imaging J Neurosci Methods 175 25 35 18762213 10.1016/j.jneumeth.2008.07.020 1:CAS:528:DC%2BD1cXhtFyls7nK
7. R Depoortere G Dargazanli G Estenne-Bouhtou A Coste C Lanneau C Desvignes M Poncelet M Heaulme V Santucci M Decobert A Cudennec C Voltz D Boulay J Paul Terranova J Stemmelin P Roger B Marabout M Sevrin X Vige B Biton R Steinberg D Francon R Alonso P Avenet F Oury-Donat G Perrault G Griebel P George P Soubrie B Scatton 2005 Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic Neuropsychopharmacology 30 1963 1985 15956994 10.1038/sj.npp.1300772 1:CAS:528:DC%2BD2MXhtFWlt7jP (Pubitemid 43093498)
8. GE Duncan KB Johnson GR Breese 1993 Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity J Neurosci 13 3932 3943 8366353 1:CAS:528:DyaK3sXms1Onur8%3D (Pubitemid 23264377)
9. GE Duncan JN Leipzig RB Mailman JA Lieberman 1998 Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation Brain Res 812 65 75 9813244 10.1016/S0006-8993(98)00926-3 1:CAS:528:DyaK1cXntVyiu7c%3D (Pubitemid 29005332)
10. GE Duncan SS Moy DJ Knapp RA Mueller GR Breese 1998 Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia Brain Res 787 181 190 9518601 10.1016/S0006-8993(97)01390-5 1:CAS:528:DyaK1cXhvFGrtr0%3D (Pubitemid 28197904)
11. GE Duncan S Miyamoto JN Leipzig JA Lieberman 2000 Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism J Pharmacol Exp Ther 293 8 14 10734147 1:CAS:528:DC%2BD3cXkvFGht78%3D (Pubitemid 30180917)
12. C Eintrei L Sokoloff CB Smith 1999 Effects of diazepam and ketamine administered individually or in combination on regional rates of glucose utilization in rat brain Br J Anaesth 82 596 602 10472230 1:CAS:528: DyaK1MXivFSku7s%3D (Pubitemid 29151246)
13. KE Gilling C Jatzke M Hechenberger CG Parsons 2009 Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors Neuropharmacology 56 866 875 19371579 10.1016/j.neuropharm.2009.01.012 1:CAS:528:DC%2BD1MXkt1Sitro%3D
14. G Gilmour EY Pioli SL Dix JW Smith MW Conway WT Jones S Loomis R Mason S Shahabi MD Tricklebank 2009 Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia Psychopharmacology (Berl) 205 203 216 10.1007/s00213-009-1530-7 1:CAS:528:DC%2BD1MXlsFOmtrk%3D
15. SD Gleason HE Shannon 1997 Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice Psychopharmacology 129 79 84 9122367 10.1007/s002130050165 1:CAS:528:DyaK2sXosVOhsg%3D%3D (Pubitemid 27037454)
16. A Gozzi CH Large A Schwarz S Bertani V Crestan A Bifone 2007 Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine Neuropsychopharmacology 33 1690 1703 17805312 10.1038/sj.npp. 1301547 (Pubitemid 351684709)
17. H Gunduz-Bruce 2009 The acute effects of NMDA antagonism: from the rodent to the human brain Brain Res Rev 60 279 286 18703087 10.1016/j.brainresrev. 2008.07.006 1:CAS:528:DC%2BD1MXls12jtr0%3D
18. HH Holcomb AC Lahti DR Medoff T Cullen CA Tamminga 2005 Effects of noncompetitive nmda receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia Neuropsychopharmacology 30 2275 2282 16034443 10.1038/sj.npp.1300824 1:CAS:528:DC%2BD2MXht1WqurvP (Pubitemid 41643980)
19. ED Huey IH Dustin GP Overman N Mirza T Sunderland 2005 Development of subtle psychotic symptoms with memantine: a case report J Clin Psychiatry 66 658 659 15889961 10.4088/JCP.v66n0519f (Pubitemid 40733715)
20. JH Krystal LP Karper JP Seibyl GK Freeman R Delaney JD Bremner GR Heninger MB Bowers Jr DS Charney 1994 Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 199 214 8122957 1:CAS:528:DyaK2cXkslemtrY%3D (Pubitemid 24081509)
21. A Kurumaji J McCulloch 1989 Effects of MK-801 upon local cerebral glucose utilisation in conscious rats and in rats anaesthetised with halothane J Cereb Blood Flow Metab 9 786 794 2684992 1:CAS:528:DyaK3cXkvVKhsQ%3D%3D (Pubitemid 20006898)
22. AC Lahti HH Holcomb DR Medoff CA Tamminga 1995 Ketamine activates psychosis and alters limbic blood flow in schizophrenia NeuroReport 6 869 872 7612873 10.1097/00001756-199504190-00011 1:CAS:528:DyaK2MXmt1CktLk%3D
23. JA Lieberman K Papadakis J Csernansky R Litman J Volavka XD Jia A Gage 2009 A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology 34 1322 1329 19005465 10.1038/npp.2008.200 1:CAS:528:DC%2BD1MXjtFentL4%3D
24. CW Lindsley WD Shipe SE Wolkenberg CR Theberge J Williams C Sur GG Kinney 2006 Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia Curr Top Med Chem 6 771 785 16719816 10.2174/156802606777057599 1:CAS:528:DC%2BD28XmtVahsLw%3D
25. AK Malhotra DA Pinals H Weingartner K Sirocco CD Missar D Pickar A Breier 1996 NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 301 307 8703299 10.1016/0893-133X(95)00137-3 1:CAS:528:DyaK28XivVGltbk%3D (Pubitemid 26151927)
26. CR Maxwell RS Ehrlichman Y Liang D Trief SJ Kanes J Karp SJ Siegel 2006 Ketamine produces lasting disruptions in encoding of sensory stimuli J Pharmacol Exp Ther 316 315 324 16192313 10.1124/jpet.105.091199 1:CAS:528: DC%2BD28XhslCjug%3D%3D (Pubitemid 41832611)
27. R Miller 2009 Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I Curr Neuropharmacol 7 302 314 20514210 10.2174/157015909790031229 1:CAS:528:DC%2BC3cXns1yq
28. S Miyamoto JN Leipzig JA Lieberman GE Duncan 2000 Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice Neuropsychopharmacology 22 400 412 10700659 10.1016/S0893-133X(99)00127-X 1:CAS:528:DC%2BD3cXhsVajsbk%3D (Pubitemid 30105768)
29. B Moghaddam B Adams A Verma D Daly 1997 Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 17 2921 2927 9092613 1:CAS:528:DyaK2sXisValurk%3D (Pubitemid 27155025)
30. JW Olney JW Newcomer NB Farber 1991 NMDA receptor hypofunction model of schizophrenia J Psychiatr Res 33 523 533 10.1016/S0022-3956(99)00029-1
31. CG Parsons A Stoffler W Danysz 2007 Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse Neuropharmacology 53 699 723 17904591 10.1016/j.neuropharm.2007.07.013 1:CAS:528:DC%2BD2sXhtFGrsLzF (Pubitemid 47532143)
32. ST Patil L Zhang F Martenyi SL Lowe KA Jackson BV Andreev AS Avedisova LM Bardenstein IY Gurovich MA Morozova SN Mosolov NG Neznanov AM Reznik AB Smulevich VA Tochilov BG Johnson JA Monn DD Schoepp 2007 Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat Med 13 1102 1107 17767166 10.1038/nm1632 1:CAS:528: DC%2BD2sXhtVSgtrvF (Pubitemid 47517511)
33. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. Academic, San Diego
34. P Riederer KW Lange J Kornhuber W Danielczyk 1991 Pharmacotoxic psychosis after memantine in Parkinson's disease Lancet 338 1022 1023 1681331 10.1016/0140-6736(91)91888-2 1:STN:280:DyaK38%2Fhs12gtA%3D%3D
35. LM Rorick-Kehn BG Johnson KM Knitowski CR Salhoff JM Witkin KW Perry KI Griffey JP Tizzano JA Monn DL McKinzie DD Schoepp 2007 In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Psychopharmacology (Berl) 193 121 136 10.1007/s00213-007-0758-3 1:CAS:528:DC%2BD2sXmtlGktr8%3D (Pubitemid 46906627)
36. WK Schiffer MM Mirrione SL Dewey 2007 Optimizing experimental protocols for quantitative behavioral imaging with 18 F-FDG in rodents J Nucl Med 48 277 287 17268026 1:CAS:528:DC%2BD2sXjsVKmsbs%3D (Pubitemid 47555355)
37. L Sokoloff M Reivich C Kennedy MH Des Rosiers CS Patlak KD Pettigrew O Sakurada M Shinohara 1977 The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat J Neurochem 28 897 916 864466 10.1111/j.1471-4159.1977.tb10649.x 1:CAS:528:DyaE2sXltlWiuro%3D (Pubitemid 8098854)
38. D Spiegel M Leader 2007 Psychosis induced by the interaction of memantine and amantadine: lending evidence to the glutamatergic theory of schizophrenia Clin Schizophr Relat Psychoses 1 273 276 10.3371/CSRP.1.3.7
39. FX Vollenweider KL Leenders I Oye D Hell J Angst 1997 Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) Eur Neuropsychopharmacol 7 25 38 9088882 10.1016/S0924-977X(96)00042-9 1:CAS:528:DyaK2sXhtlyisr0%3D (Pubitemid 27139717)
40. FX Vollenweider KL Leenders C Scharfetter A Antonini P Maguire J Missimer J Angst 1997 Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) Eur Neuropsychopharmacol 7 9 24 9088881 10.1016/S0924-977X(96)00039-9 1:CAS:528:DyaK2sXhtlyisrw%3D (Pubitemid 27139716)
41. G Warnock D Moechars X Langlois T Steckler 2009 In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization Peptides 30 947 954 19428773 10.1016/j.peptides.2009.01.005 1:CAS:528:DC%2BD1MXltlKrsbw%3D
42. HU Zeilhofer D Swandulla G Geisslinger K Brune 1992 Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons Eur J Pharmacol 213 155 158 1386806 10.1016/0014-2999(92)90248-3 1:CAS:528: DyaK38XisVOqs78%3D